Verition Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-83,700
Closed -$9.68M 2826
2023
Q3
$9.68M Sell
83,700
-10,000
-11% -$1.07M 0.11% 226
2023
Q2
$9.64M Buy
+93,700
New +$9.89M 0.13% 209
2022
Q2
Sell
-30,000
Closed -$3.16M 3341
2022
Q1
$3.16M Hold
30,000
0.04% 641
2021
Q4
$3.23M Buy
+30,000
New +$3.27M 0.02% 576

Other funds holding HZNP

Verition Fund Management's HZNP Position: Q4 2023 in Review

Verition Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 367,671 shares — an estimated $42.5M sold.

Verition Fund Management first reported a position in HZNP in Q4 2013 and held it in 12 quarters. The position peaked at $96.6M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Verition Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 367,671 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $42.5M.
  • Verition Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 12 quarters.
  • Verition Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $96.6M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.